{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:23:40Z","timestamp":1792783420786,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,2,4]],"date-time":"2024-02-04T00:00:00Z","timestamp":1707004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,4]],"date-time":"2024-02-04T00:00:00Z","timestamp":1707004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"French ministry of Health","award":["PHRC 2017"],"award-info":[{"award-number":["PHRC 2017"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s40262-023-01342-3","type":"journal-article","created":{"date-parts":[[2024,2,4]],"date-time":"2024-02-04T04:01:52Z","timestamp":1707019312000},"page":"333-342","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Lumacaftor\/Ivacaftor Population Pharmacokinetics in Pediatric Patients with Cystic Fibrosis: A First Step Toward Personalized Therapy"],"prefix":"10.1007","volume":"63","author":[{"given":"Na\u00efm","family":"Bouazza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa\u00efk","family":"Urien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frantz","family":"Foissac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Choupeaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Lui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9o","family":"Froelicher Bournaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steeve","family":"Rouillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Bardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Stremler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Bessaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiphaine","family":"Bihouee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Coirier-Duet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Marguet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Deneuville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muriel","family":"Laurans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Reix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mich\u00e8le","family":"Gerardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Mittaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Epaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Thumerelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Berthaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Semeraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Treluyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sihem","family":"Benaboud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Sermet-Gaudelus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,4]]},"reference":[{"issue":"9678","key":"1342_CR1","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1016\/S0140-6736(09)60327-5","volume":"373","author":"BP O\u2019Sullivan","year":"2009","unstructured":"O\u2019Sullivan BP, Freedman SD. Cystic fibrosis. Lancet. 2009;373(9678):1891\u2013904.","journal-title":"Lancet"},{"key":"1342_CR2","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.biocel.2014.03.020","volume":"52","author":"IM Pranke","year":"2014","unstructured":"Pranke IM, Sermet-Gaudelus I. Biosynthesis of cystic fibrosis transmembrane conductance regulator. Int J Biochem Cell Biol. 2014;52:26\u201338.","journal-title":"Int J Biochem Cell Biol"},{"key":"1342_CR3","doi-asserted-by":"publisher","first-page":"113195","DOI":"10.1016\/j.ejmech.2021.113195","volume":"213","author":"E Bardin","year":"2021","unstructured":"Bardin E, Pastor A, Semeraro M, Golec A, Hayes K, Chevalier B, et al. Modulators of CFTR. Updates on clinical development and future directions. Eur J Med Chem. 2021;213:113195.","journal-title":"Eur J Med Chem"},{"key":"1342_CR4","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.3389\/fphar.2019.01662","volume":"10","author":"M Lopes-Pacheco","year":"2020","unstructured":"Lopes-Pacheco M. CFTR modulators: the changing face of cystic fibrosis in the era of precision medicine. Front Pharmacol. 2020;10:1662.","journal-title":"Front Pharmacol"},{"key":"1342_CR5","unstructured":"Multi-discipline review. 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/211358Orig1s000MultidisciplineR.pdf."},{"issue":"8","key":"1342_CR6","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.3390\/pharmaceutics14081674","volume":"14","author":"E Choong","year":"2022","unstructured":"Choong E, Sauty A, Koutsokera A, Blanchon S, Andr\u00e9 P, Decosterd L. Therapeutic drug monitoring of ivacaftor, lumacaftor, tezacaftor, and elexacaftor in cystic fibrosis: where are we now? Pharmaceutics. 2022;14(8):1674.","journal-title":"Pharmaceutics"},{"issue":"3","key":"1342_CR7","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1056\/NEJMoa1409547","volume":"373","author":"CE Wainwright","year":"2015","unstructured":"Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, et al. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med. 2015;373(3):220\u201331.","journal-title":"N Engl J Med"},{"issue":"3","key":"1342_CR8","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.jcf.2017.03.003","volume":"16","author":"D Hubert","year":"2017","unstructured":"Hubert D, Chiron R, Camara B, Grenet D, Pr\u00e9votat A, Bassinet L, et al. Real-life initiation of lumacaftor\/ivacaftor combination in adults with cystic fibrosis homozygous for the Phe508del CFTR mutation and severe lung disease. J Cyst Fibros. 2017;16(3):388\u201391.","journal-title":"J Cyst Fibros"},{"issue":"12","key":"1342_CR9","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1056\/NEJMra035092","volume":"349","author":"GL Kearns","year":"2003","unstructured":"Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology\u2014drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349(12):1157\u201367.","journal-title":"N Engl J Med"},{"issue":"6","key":"1342_CR10","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1183\/09031936.00080312","volume":"40","author":"PH Quanjer","year":"2012","unstructured":"Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic reference values for spirometry for the 3\u201395-yr age range: the global lung function 2012 equations. Eur Respir J. 2012;40(6):1324\u201343.","journal-title":"Eur Respir J"},{"issue":"9","key":"1342_CR11","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1002\/jps.23574","volume":"102","author":"N Holford","year":"2013","unstructured":"Holford N, Heo YA, Anderson B. A pharmacokinetic standard for babies and adults. J Pharm Sci. 2013;102(9):2941\u201352.","journal-title":"J Pharm Sci"},{"key":"1342_CR12","unstructured":"203188Orig1s000ClinPharmR.pdf [Internet]. Disponible sur. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/203188Orig1s000ClinPharmR.pdf. Accessed 30 Nov 2023."},{"key":"1342_CR13","unstructured":"206038s016lbl.pdf [Internet]. Disponible sur. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/206038s016lbl.pdf. Accessed 17 Mar 2023."},{"issue":"2","key":"1342_CR14","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jcf.2019.09.006","volume":"19","author":"S van Koningsbruggen-Rietschel","year":"2020","unstructured":"van Koningsbruggen-Rietschel S, Conrath K, Fischer R, Sutharsan S, Kempa A, Gleiber W, et al. GLPG2737 in lumacaftor\/ivacaftor-treated CF subjects homozygous for the F508del mutation: a randomized phase 2A trial (PELICAN). J Cyst Fibros. 2020;19(2):292\u20138.","journal-title":"J Cyst Fibros"},{"issue":"12","key":"1342_CR15","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","volume":"203","author":"ET Zemanick","year":"2021","unstructured":"Zemanick ET, Taylor-Cousar JL, Davies J, Gibson RL, Mall MA, McKone EF, et al. A phase 3 open-label study of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del allele. Am J Respir Crit Care Med. 2021;203(12):1522\u201332.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"1342_CR16","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s41030-020-00124-7","volume":"6","author":"A Tsai","year":"2020","unstructured":"Tsai A, Wu SP, Haseltine E, Kumar S, Moskowitz SM, Panorchan P, et al. Physiologically based pharmacokinetic modeling of CFTR modulation in people with cystic fibrosis transitioning from mono or dual regimens to triple-combination elexacaftor\/tezacaftor\/ivacaftor. Pulm Ther. 2020;6(2):275\u201386.","journal-title":"Pulm Ther"},{"issue":"6","key":"1342_CR17","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3109\/02770909909054554","volume":"36","author":"S Teramoto","year":"1999","unstructured":"Teramoto S, Suzuki M, Matsui H, Ishii T, Matsuse T, Ouchi Y. Influence of age on diurnal variability in measurements of spirometric indices and respiratory pressures. J Asthma. 1999;36(6):487\u201392.","journal-title":"J Asthma"},{"issue":"1","key":"1342_CR18","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/ppul.1950080107","volume":"8","author":"PJ Cooper","year":"1990","unstructured":"Cooper PJ, Robertson CF, Hudson IL, Phelan PD. Variability of pulmonary function tests in cystic fibrosis. Pediatr Pulmonol. 1990;8(1):16\u201322.","journal-title":"Pediatr Pulmonol"},{"issue":"6","key":"1342_CR19","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1378\/chest.08-1190","volume":"135","author":"AL Quittner","year":"2009","unstructured":"Quittner AL, Modi AC, Wainwright C, Otto K, Kirihara J, Montgomery AB. Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest. 2009;135(6):1610\u20138.","journal-title":"Chest"},{"issue":"3","key":"1342_CR20","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.jcf.2018.12.011","volume":"18","author":"A Masson","year":"2019","unstructured":"Masson A, Schneider-Futschik EK, Baatallah N, Nguyen-Khoa T, Girodon E, Hatton A, et al. Predictive factors for lumacaftor\/ivacaftor clinical response. J Cyst Fibros. 2019;18(3):368\u201374.","journal-title":"J Cyst Fibros"},{"issue":"6","key":"1342_CR21","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.jcf.2022.09.005","volume":"21","author":"I Sermet-Gaudelus","year":"2022","unstructured":"Sermet-Gaudelus I, Girodon E, Vermeulen F, Solomon GM, Melotti P, Graeber SY, et al. ECFS standards of care on CFTR-related disorders: diagnostic criteria of CFTR dysfunction. J Cyst Fibros. 2022;21(6):922\u201336.","journal-title":"J Cyst Fibros"},{"issue":"4","key":"1342_CR22","doi-asserted-by":"publisher","first-page":"2300110","DOI":"10.1183\/13993003.00110-2023","volume":"62","author":"E Dreano","year":"2023","unstructured":"Dreano E, Burgel PR, Hatton A, Bouazza N, Chevalier B, Macey J, et al. Theratyping cystic fibrosis patients to guide elexacaftor\/tezacaftor\/ivacaftor out-of-label prescription. Eur Respir J. 2023;62(4):2300110.","journal-title":"Eur Respir J"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-023-01342-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-023-01342-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-023-01342-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T07:33:07Z","timestamp":1710919987000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-023-01342-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,4]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["1342"],"URL":"https:\/\/doi.org\/10.1007\/s40262-023-01342-3","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,4]]},"assertion":[{"value":"19 December 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was supported by a grant from the French Ministry of Health (PHRC 2017, PREDICT-CF). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have no competing interests to declare in relation to this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the institutional review board (Comit\u00e9 de Protection des Personnes, Nord Ouest IV, no. EUDRACT: 2018-002624-16) and registered in the clinicaltrails.gov database under reference NCT03894657.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written, informed consent was obtained from all participants or their guardians.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data from this study cannot be shared publicly, as the procedures carried out with the French data privacy authority [Commission nationale de l'informatique et des libert\u00e9s (CNIL)] do not provide for the transmission of the database, nor do the information and consent documents signed by the patients. Consultation of the data by other interested researchers may be considered by AP-HP, subject to prior determination of the terms and conditions of such consultation and in respect for compliance with the applicable French and European regulations. The request must be addressed to the Delegation for Clinical Research and Innovation (DRCI) at <u>secretariat-direction.drc@aphp.fr<\/u>.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"NB, JMT, and ISG contributed to the study conception and design. Material preparation, data collection, and analysis were performed by NB, SU, FF, LC, GL, LFD, SR, YZ, NS, KB, TB, ECD, CM, ED, ML, PR, MG, MM, RE, CT, LW, RB, MS, SB, and ISG. The first draft of the manuscript was written by NB, EB, ISG, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}